Watchful waiting vs. medication for tissue after early abortion
Part of Women’s health & pregnancy clinical trials.
This study compares two approaches for managing retained pregnancy tissue (leftover tissue in the uterus after a medical abortion): waiting to see if your body passes it naturally versus taking medication to help remove it. The goal is to find out which approach works better and is safer for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 45 years old
- Have had a medical abortion (medication-based, not surgical) and have retained tissue confirmed by ultrasound
- Be in stable health with normal bleeding (like a period) and no fever
- Not have excessive bleeding, signs of infection, or hemodynamic instability (dangerously low blood pressure)
- Not have already taken two doses of misoprostol (a medication that helps expel tissue)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether managing a condition where pregnancy tissue remains in the womb (called retained products of conception) without immediate surgery is safe and effective. It might be an option for people who are stable and want to avoid more invasive procedures.
This trial studies the best way to remove leftover pregnancy tissue after a first-trimester miscarriage. It compares approaches guided by a camera procedure in the uterus to see which helps most, especially for people who want to get pregnant again soon.
This study follows patients with retained products of conception (tissue left in the uterus after a pregnancy) to see how they are managed in real-world medical practice. You may join if an ultrasound shows a tissue area of at least half a centimeter.
This study compares two ways of taking medicine (by mouth or vaginal insertion) to safely manage a miscarriage that was discovered on ultrasound between 8–16 weeks of pregnancy. The goal is to see which method works better and causes fewer side effects.
This study compares two medications—letrozole plus misoprostol versus misoprostol alone—to see which is more effective for ending a pregnancy in the second trimester (14–20 weeks) after the fetus has stopped developing. The goal is to find a safer, more comfortable method for women who need this procedure.
This trial tests two different medicines (Mifepristone vs Misoprostol) to see which works better for ending a pregnancy in the second trimester (12–16 weeks). It is for people who are pregnant with one baby and have no major health issues that could affect safety.
Hear when a new Retained Product of Conception After First Trimester Medical Abortion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.